CARCINOMA, NON-SMALL-CELL LUNG

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…

This study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …

This study tests several new drug combinations, including pembrolizumab (an immunotherapy), with or without chemotherapy, in people with advanced non-small cell lung cancer who have not had prior treatment. The goal is to see if these combinations can shrink tumors and control th…

This Phase 2 study tests two new antibody-drug conjugates (R-DXd and I-DXd) against standard chemotherapy in 96 people with advanced nonsquamous non-small cell lung cancer that has worsened after prior immunotherapy and chemotherapy. These 'guided missiles' deliver a cancer-killi…

This early-stage trial is testing a new drug called JNJ-86974680, alone or with another drug (cetrelimab) and radiation, in people with advanced non-small cell lung cancer. The main goal is to find a safe and tolerable dose. About 126 participants will be enrolled. The study is c…

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This phase 3 trial tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 630 adults who have not had …

This Phase 3 study tests whether adding olomorasib (a targeted pill) to standard immunotherapy (pembrolizumab or durvalumab) works better than immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer. The trial has two parts: one for patients whose cancer w…

This global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This phase 2 trial tests a drug called navlimetostat in about 130 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has worsened after other treatments. The main goal is to see if the drug can shrink tumors. Resea…

This study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…

This study tests a combination of two drugs, amivantamab and olomorasib, in people with a specific type of advanced lung cancer (KRAS G12C mutant NSCLC) that has spread. The goal is to find the safest and most effective dose and see if the combo can shrink tumors or slow their gr…

This phase 2 trial is testing amivantamab, a targeted cancer drug, given as a simple shot under the skin (instead of an IV drip) in people with advanced non-small cell lung cancer that has specific EGFR mutations. The study will enroll about 520 participants across several groups…

This study tests whether adding an experimental drug (JNJ-90301900) to standard chemoradiation and a follow-up immunotherapy (durvalumab) can shrink tumors more effectively in people with locally advanced, inoperable stage III non-small cell lung cancer. About 130 participants wi…

This study follows 800 Chinese patients with early-stage ALK-positive non-small-cell lung cancer who took alectinib after surgery to see how long they stay cancer-free. Researchers will collect real-world data on disease-free survival and patient characteristics. The goal is to u…

This study tests a new treatment for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). Participants receive either a combination of two drugs (amivantamab and lazertinib) as their first treatment, or amivantamab with chemotherapy if …

This study tests a new experimental drug called PF-08634404 combined with other cancer medicines in people with advanced non-small cell lung cancer that has spread and can't be surgically removed. The trial has two parts: one combining PF-08634404 with sigvotatug vedotin, and ano…

This early-stage trial tests the safety of honokiol, a dietary supplement from magnolia bark, in 15 people with early lung cancer. Participants take honokiol for two weeks before their scheduled surgery. The goal is to find the highest safe dose and check for side effects.

This phase 3 trial tests whether two immunotherapy drugs, sacituzumab and zimberelimab, can keep lung cancer from returning after surgery. It includes 129 patients whose cancer did not fully disappear with pre-surgery treatment. Participants are split into three groups: observati…

This phase 3 study compares a new biologic drug, rilvegostomig, to the standard drug pembrolizumab (Keytruda) as a first treatment for people with advanced non-small cell lung cancer that has high PD-L1 levels. About 830 participants worldwide will receive either drug by IV every…

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…

This study tests whether adding the experimental drug LP-300 to standard chemotherapy can help people who have never smoked and have advanced lung cancer that has returned after targeted therapy. About 90 participants will receive either the drug combo or chemo alone. The goal is…

This phase 2 trial tests whether combining the immunotherapy drug cemiplimab with either chemotherapy or targeted radiation (SBRT) before surgery can eliminate or shrink non-small cell lung cancer more effectively. About 112 people with stage IB to III (N2) lung cancer will recei…

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This Phase 3 trial tests whether adding Sigvotatug Vedotin to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 participants will receive either the combinati…

This early-phase study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…

This early-stage study tests a new experimental drug called PF-07934040, taken as a pill, for people with advanced solid tumors that have a KRAS gene mutation. The trial includes patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Researchers will …

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This study tests whether a team of specialists—including surgeons, oncologists, and geriatricians—can create better treatment plans for elderly lung cancer patients. 2,000 people aged 60-90 will receive personalized care based on their overall health and cancer type. The goal is …

This early-stage study tests a new drug called AST-201 in about 70 adults with advanced solid tumors that have a protein called GPC3. The main goal is to check the drug's safety and find the right dose. Researchers will also measure how the drug moves through the body and look fo…

This phase 2 trial tests a combination of pemetrexed (given into the spinal fluid) and a tyrosine kinase inhibitor for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis) after the d…

This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy is safe and effective for people with HIV who have advanced non-small cell lung cancer. About 18 participants will receive the treatment, and researchers will monitor si…

This phase 2 trial tests whether a blood test that tracks tumor DNA can guide treatment for people with advanced non-small cell lung cancer. Participants will receive either immunotherapy alone or immunotherapy plus chemotherapy, based on their blood test results. The goal is to …

This pilot study tests whether giving a higher dose of proton therapy to the lung tumor is safe for people with stage III non-small-cell lung cancer who are also getting chemotherapy. About 87 participants will receive the higher radiation dose along with standard chemo drugs. Re…

This study tests an experimental gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the drug osimertinib (Tagrisso) in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has stopped responding to osimertinib alone. The gene therapy delivers…

This early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…

This phase 3 trial tests whether a new drug called THIO, given before the immunotherapy cemiplimab, can help people with advanced non-small cell lung cancer who have already tried two prior treatments. About 300 participants will be randomly assigned to receive either the THIO-ce…

This study compares a new drug, BAT3306, to the approved drug Keytruda in people with stage IB-IIIA non-small cell lung cancer whose tumors have been completely removed by surgery. The goal is to see if BAT3306 works similarly as an additional treatment to help keep the cancer fr…

This phase 2 trial is testing whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can help keep locally advanced non-small cell lung cancer from progressing. About 42 patients who cannot have surgery will receive the boost. The main goal…

This study is monitoring the safety and effectiveness of the drug brigatinib in adults with a specific type of advanced lung cancer (ALK-positive NSCLC) in South Korea. Researchers will track side effects and how well the drug controls the cancer in 257 patients who are starting …

This trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…

This early-phase study tests a new radioactive imaging agent called [68Ga]Ga-DWJ155 in 36 adults with advanced breast cancer or non-small cell lung cancer. The agent is designed to bind to a target on cancer cells and show up on PET scans, helping doctors see where the cancer has…

This study compares standard bronchoscopy (using a thin tube to look at the lungs) with and without an additional laser-based microscope called nCLE. The microscope helps doctors see if the sampling needle is in the right spot before taking tissue. About 208 adults with suspiciou…

This study is testing a new program called POISE for people with stage IV non-small cell lung cancer who are on targeted therapy. The program includes four visits with a specially trained palliative care clinician to help patients cope with uncertainty and manage their cancer. Re…

This large study is testing many different drug combinations, including the immunotherapy pembrolizumab, in people with advanced non-small cell lung cancer. The goal is to see which treatments work best based on specific tumor features like PD-L1 levels and histology. Over 1,000 …

This study is observing 380 people with a common type of advanced lung cancer caused by EGFR mutations who are receiving amivantamab as part of their routine care. Researchers will track how long patients stay on treatment and how well it controls the cancer in everyday medical p…

This study looks at how bone tumors respond to treatment in people with non-small cell lung cancer. Researchers will measure bone health markers in urine and blood before and after treatment. The goal is to see if targeted pills (TKIs) or standard treatments like chemotherapy or …

This study follows 7,500 people with newly diagnosed non-small cell lung cancer to see how quickly they get biomarker tests and whether those tests help doctors choose the right treatment. Researchers want to find out what slows down testing, such as tissue problems or insurance …

This study is collecting blood and tumor samples from 730 newly diagnosed lung cancer patients at Nantes University Hospital. Researchers will follow patients from diagnosis until death to understand how treatments work in real life, especially for patients often left out of clin…

This study is a registry that will collect information from about 3,750 adults with lung cancer across 21 hospitals in Algeria. Researchers will track patients' health, treatments, and outcomes during routine care. The goal is to better understand lung cancer in Algeria and help …